The clonoSEQ Assay is claimed to be the first and only in vitro diagnostic (IVD) test approved by the US Food and Drug Administration (FDA) for identifying minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukaemia (B-ALL) and chronic lymphocytic leukaemia (CLL).
The integration will help provide easy access to clonoSEQ testing and fuse results seamlessly into patient records through the EMR system, allowing streamlined clinical decision-making for oncologists.
It will also allow providers to order and evaluate clonoSEQ results from Adaptive in a similar manner to other tests performed directly at the site of care.
The integration enables cancer care providers using Epic in institutions and practices across the US to simplify their MRD testing workflows.
With clonoSEQ integration expected to go live next year, Adaptive’s work with Epic will begin immediately.
Adaptive Biotechnologies MRD chief commercial officer Nitin Sood said: “EMR integration is clearly the path forward to expanding access and increasing ease of use for advanced oncology tests like clonoSEQ.
“MRD is most powerful when monitored serially over time, and Epic integration will enable providers to efficiently leverage clonoSEQ MRD results at multiple points in the patient care continuum.”
Leveraging Adaptive’s immune medicine platform, the clonoSEQ Assay will detect and quantify specific DNA sequences found in malignant cells. It will help clinicians study and monitor MRD during and after treatment.
By providing a standardised, accurate and sensitive MRD measurement, the assay will enable physicians to predict patient outcomes, evaluate therapy response over time, monitor patients at the time of remission and predict potential relapse.